Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
debunking-puberty-blockers [2025/12/29 11:43] – valahdebunking-puberty-blockers [2025/12/29 15:21] (current) – [References] valah
Line 237: Line 237:
 **Critical point:** An agenda-driven government report with hidden authorship is not evidence of harm. **Critical point:** An agenda-driven government report with hidden authorship is not evidence of harm.
  
 +[[https://valah.blog/disinformation-by-design-hhs-report-2025/|You can read the initial analysis I wrote about it here]]
  
 ===== What Would Actually Constitute Evidence of Harm? ===== ===== What Would Actually Constitute Evidence of Harm? =====
Line 242: Line 243:
 **Evidence would require:** **Evidence would require:**
  
-1. **Documented adverse outcomes** in large populations +  * **Documented adverse outcomes** in large populations 
-2. **Causation demonstrated** (not just correlation) +  * **Causation demonstrated** (not just correlation) 
-3. **Comparison to control groups** (what happens without care) +  * **Comparison to control groups** (what happens without care) 
-4. **Peer-reviewed publication** in mainstream journals +  * **Peer-reviewed publication** in mainstream journals 
-5. **Independent verification** by researchers without political agenda+  * **Independent verification** by researchers without political agenda
  
 **What we have instead:** **What we have instead:**
  
-- Meta-analyses showing **benefits** (reduced suicidality, depression, anxiety) +  * Meta-analyses showing **benefits** (reduced suicidality, depression, anxiety) 
-- Randomized controlled trials showing **safety** +  * Randomized controlled trials showing **safety** 
-- Major medical organizations supporting care based on evidence +  * Major medical organizations supporting care based on evidence 
-- Two government reviews making **recommendations for caution**, not proving harm exists+  * Two government reviews making **recommendations for caution**, not proving harm exists
  
  
Line 260: Line 261:
 **What transphobes demand:** **What transphobes demand:**
  
-- Absolute proof that puberty blockers help (which exists) +  - Absolute proof that puberty blockers help (which exists) 
-- But simultaneously, they claim Cass and HHS prove harm, even though these reports:+  - But simultaneously, they claim Cass and HHS prove harm, even though these reports:
   - Don't document net harm   - Don't document net harm
   - Recommended research, not bans   - Recommended research, not bans
Line 269: Line 270:
 **What they ignore:** **What they ignore:**
  
-- Evidence that withholding care causes demonstrable harm (2-3x increase in depression/suicidality) [(pb37)] +  * Evidence that withholding care causes demonstrable harm (2-3x increase in depression/suicidality) [(pb37)] 
-- That major medical organizations—based on actual evidence review—support gender-affirming care +  * That major medical organizations—based on actual evidence review—support gender-affirming care 
-- That both the Cass Review and HHS report faced serious academic and professional critique+  * That both the Cass Review and HHS report faced serious academic and professional critique
  
  
Line 330: Line 331:
 [(pb6> Steensma, T. D., McGuire, J. K., Kreukels, B. P., Beekman, A. J., & Cohen-Kettenis, P. T. (2013). Factors associated with desistence and persistence of childhood gender dysphoria: A quantitative follow-up study. Journal of the American Academy of Child & Adolescent Psychiatry, 52(6), 582–590. https://pubmed.ncbi.nlm.nih.gov/23702447/ .)] [(pb6> Steensma, T. D., McGuire, J. K., Kreukels, B. P., Beekman, A. J., & Cohen-Kettenis, P. T. (2013). Factors associated with desistence and persistence of childhood gender dysphoria: A quantitative follow-up study. Journal of the American Academy of Child & Adolescent Psychiatry, 52(6), 582–590. https://pubmed.ncbi.nlm.nih.gov/23702447/ .)]
  
-[(pb7> Planned Parenthood. (2021). What are puberty blockers? Retrieved from https://www.plannedparenthood.org/learn/teens/ask-experts/what-are-puberty-blockers .)]+[(pb7> Planned Parenthood. (2021). What are puberty blockers? Retrieved from https://www.plannedparenthood.org/learn/teens/puberty/what-are-puberty-blockers .)]
  
 [(pb8> Carswell, J. M., Finlayson, C., Bartolucci, A. A., Chen, D., & Hanna, S. (2022). The evolution of adolescent gender-affirming care. Hormone Research in Paediatrics, 95(6), 649–661. https://pubmed.ncbi.nlm.nih.gov/36446328/ .)] [(pb8> Carswell, J. M., Finlayson, C., Bartolucci, A. A., Chen, D., & Hanna, S. (2022). The evolution of adolescent gender-affirming care. Hormone Research in Paediatrics, 95(6), 649–661. https://pubmed.ncbi.nlm.nih.gov/36446328/ .)]
  
-[(pb9> Safer, J. D., & Coleman, E. (2016). Hormone therapy in transgender adults is safe with provider supervision. Journal of Clinical Endocrinology & Metabolism, 101(12), 4422–4426. .)]+[(pb9> Safer, J. D., & Coleman, E. (2016). Hormone therapy in transgender adults is safe with provider supervision. Journal of Clinical Endocrinology & Metabolism, 101(12), 4422–4426.https://pubmed.ncbi.nlm.nih.gov/28090436/ .)]
  
-[(pb10> Schagen, S. E., Cohen-Kettenis, P. T., Delemarre-van de Waal, H. A., & Hannema, S. E. (2016). Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. The Journal of Adolescent Health, 59(3), 330–337. .)]+[(pb10> Schagen, S. E., Cohen-Kettenis, P. T., Delemarre-van de Waal, H. A., & Hannema, S. E. (2016). Efficacy and safety of gonadotropin-releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. The Journal of Adolescent Health, 59(3), 330–337.https://pubmed.ncbi.nlm.nih.gov/27318023/ .)]
  
 [(pb11> Ibid. .)] [(pb11> Ibid. .)]
Line 344: Line 345:
 [(pb13> Ibid. .)] [(pb13> Ibid. .)]
  
-[(pb14> Arnoldussen, M., Steensma, T. D., Popma, A., van de Grift, T. C., Groote de Percin, S., & Cohen-Kettenis, P. T. (2022). Association between pre-treatment IQ and educational achievement after gender-affirming treatment including puberty suppression. Child Development, 93(3), 645–658. .)]+[(pb14> Arnoldussen, M., Steensma, T. D., Popma, A., van de Grift, T. C., Groote de Percin, S., & Cohen-Kettenis, P. T. (2022). Association between pre-treatment IQ and educational achievement after gender-affirming treatment including puberty suppression. Child Development, 93(3), 645–658.https://pubmed.ncbi.nlm.nih.gov/31473831/ .)]
  
 [(pb15> Transfemscience. (2022). Puberty blockers and cognitive development in transgender youth. Retrieved from https://transfemscience.org/ .)] [(pb15> Transfemscience. (2022). Puberty blockers and cognitive development in transgender youth. Retrieved from https://transfemscience.org/ .)]
Line 356: Line 357:
 [(pb19> U.S. Food and Drug Administration. (2022). FDA adds warnings about pseudotumor cerebri to labeling for GnRH agonists. FDA News. https://www.fda.gov/news-events/ .)] [(pb19> U.S. Food and Drug Administration. (2022). FDA adds warnings about pseudotumor cerebri to labeling for GnRH agonists. FDA News. https://www.fda.gov/news-events/ .)]
  
-[(pb20> Austin, S. B., Ziyadeh, N. J., Corliss, H. L., Rosario, M., Wypij, D., Haines, J., Jackson, B., Tandon, S. D., Miao, J., & Frazier, A. L. (2009). Sexual orientation disparities in pubertal timing in girls and boys. American Journal of Public Health, 99(8), 1496–1502. .)]+[(pb20> Austin, S. B., Ziyadeh, N. J., Corliss, H. L., Rosario, M., Wypij, D., Haines, J., Jackson, B., Tandon, S. D., Miao, J., & Frazier, A. L. (2009). Sexual orientation disparities in pubertal timing in girls and boys. American Journal of Public Health, 99(8), 1496–1502.https://pubmed.ncbi.nlm.nih.gov/19699419/ .)]
  
-[(pb21> Turban, J. L., King, D., Carswell, J. M., & Keuroghlian, A. S. (2022). Access to gender-affirming medical care associated with improved mental health for transgender adolescents and young adults. JAMA Network Open, 5(9), e2232980. .)]+[(pb21> Turban, J. L., King, D., Carswell, J. M., & Keuroghlian, A. S. (2022). Access to gender-affirming medical care associated with improved mental health for transgender adolescents and young adults. JAMA Network Open, 5(9), e2232980.https://pubmed.ncbi.nlm.nih.gov/31974216/ .)]
  
-[(pb22> Glynn, T. R., & van den Berg, J. J. (2017). A systematic review of interventions to reduce problematic substance use among transgender individuals. Transgender Health, 2(1), 159–177. .)]+[(pb22> Glynn, T. R., & van den Berg, J. J. (2017). A systematic review of interventions to reduce problematic substance use among transgender individuals. Transgender Health, 2(1), 159–177.https://pubmed.ncbi.nlm.nih.gov/28861547/ .)]
  
 [(pb23> Olson, K. R., Durwood, L., Baams, L., Cassinat, J. E., Deutsch, M. B., & Pfaff, C. W. (2022). Gender identity 5 years after social transition. Pediatrics, 150(2), e2021056082. https://publications.aap.org/pediatrics/article/150/2/e2021056082/186992/ .)] [(pb23> Olson, K. R., Durwood, L., Baams, L., Cassinat, J. E., Deutsch, M. B., & Pfaff, C. W. (2022). Gender identity 5 years after social transition. Pediatrics, 150(2), e2021056082. https://publications.aap.org/pediatrics/article/150/2/e2021056082/186992/ .)]
Line 366: Line 367:
 [(pb24> Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Ehrensaft, D., Fraser, L., Garofalo, R., Karasic, D. H., Knudson, G. A., et al. (2012). Standards of care for the health of transsexual, transgender, and gender-nonconforming people, Version 7. International Journal of Transgenderism, 13(4), 165–232. .)] [(pb24> Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Ehrensaft, D., Fraser, L., Garofalo, R., Karasic, D. H., Knudson, G. A., et al. (2012). Standards of care for the health of transsexual, transgender, and gender-nonconforming people, Version 7. International Journal of Transgenderism, 13(4), 165–232. .)]
  
-[(pb25> Austin, A., Craig, S. L., & D'Souza, S. A. (2018). An APA handbook of research in stigma, discrimination, and health. American Psychological Association. .)]+[(pb25> Austin, A., Craig, S. L., & D'Souza, S. A. (2018). An APA handbook of research in stigma, discrimination, and health. American Psychological Association.https://psycnet.apa.org/record/2017-53490-001 .)]
  
-[(pb26> Bariola, E., Lyons, A., Leonard, W., Pitts, M., Badcock, P., & Couch, M. (2015). Demographic and psychosocial factors associated with psychological distress and resilience in transgender individuals. The American Journal of Public Health, 105(10), 2108–2116. .)]+[(pb26> Bariola, E., Lyons, A., Leonard, W., Pitts, M., Badcock, P., & Couch, M. (2015). Demographic and psychosocial factors associated with psychological distress and resilience in transgender individuals. The American Journal of Public Health, 105(10), 2108–2116.https://pubmed.ncbi.nlm.nih.gov/26270284/ .)]
  
 [(pb27> Cass Review. (2024). Final Report. Available at: https://cass.independent-review.uk/home/publications/final-report/ .)] [(pb27> Cass Review. (2024). Final Report. Available at: https://cass.independent-review.uk/home/publications/final-report/ .)]
Line 390: Line 391:
 [(pb36> Ibid. .)] [(pb36> Ibid. .)]
  
-[(pb37> Turban, J. L., King, D., Carswell, J. M., & Keuroghlian, A. S. (2022). Access to gender-affirming medical care associated with improved mental health for transgender adolescents and young adults. JAMA Network Open, 5(9), e2232980. .)]+[(pb37> Turban, J. L., King, D., Carswell, J. M., & Keuroghlian, A. S. (2022). Access to gender-affirming medical care associated with improved mental health for transgender adolescents and young adults. JAMA Network Open, 5(9), e2232980.https://pubmed.ncbi.nlm.nih.gov/31974216/ .)]
  
 [(pb38> Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T'Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 102(10), 3869–3903. https://academic.oup.com/jcem/article/102/10/3869/4157558 .)] [(pb38> Hembree, W. C., Cohen-Kettenis, P. T., Gooren, L., Hannema, S. E., Meyer, W. J., Murad, M. H., Rosenthal, S. M., Safer, J. D., Tangpricha, V., & T'Sjoen, G. G. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 102(10), 3869–3903. https://academic.oup.com/jcem/article/102/10/3869/4157558 .)]

Trace:

Print/export
QR Code
QR Code debunking-puberty-blockers (generated for current page)